FY2024 EPS Estimates for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Cut by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at Chardan Capital decreased their FY2024 EPS estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings of ($2.93) per share for the year, down from their previous estimate of ($2.54). Chardan Capital currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($2.65) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting analysts’ consensus estimates of ($0.64).

Other equities analysts have also issued research reports about the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. HC Wainwright decreased their target price on shares of Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Robert W. Baird began coverage on shares of Lexeo Therapeutics in a research note on Thursday, June 13th. They issued an “outperform” rating and a $28.00 target price for the company. Finally, Baird R W raised Lexeo Therapeutics to a “strong-buy” rating in a research report on Thursday, June 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Lexeo Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.14.

Lexeo Therapeutics Trading Up 2.4 %

LXEO opened at $12.17 on Monday. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The firm has a market cap of $400.94 million and a price-to-earnings ratio of -0.55. Lexeo Therapeutics has a 12 month low of $9.00 and a 12 month high of $22.33. The stock has a fifty day moving average price of $13.95 and a 200-day moving average price of $14.43.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently modified their holdings of LXEO. Eventide Asset Management LLC acquired a new position in Lexeo Therapeutics in the fourth quarter valued at approximately $40,298,000. Janus Henderson Group PLC lifted its stake in shares of Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after purchasing an additional 210,047 shares during the period. Omega Fund Management LLC purchased a new stake in Lexeo Therapeutics during the fourth quarter worth $28,955,000. Artal Group S.A. grew its position in Lexeo Therapeutics by 32.9% during the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock valued at $12,571,000 after buying an additional 198,281 shares during the period. Finally, Blackstone Inc. purchased a new position in Lexeo Therapeutics in the fourth quarter valued at $9,342,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Insider Buying and Selling at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $11.53, for a total value of $57,650.00. Following the sale, the chief executive officer now owns 120,695 shares in the company, valued at $1,391,613.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.50% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.